AGP Executive Report
Last update: 7 hours agoCannabis Withdrawal Treatment: PleoPharma kicked off a pivotal Phase 3 trial for PP-01, aiming to help adults with cannabis use disorder manage withdrawal symptoms. CBD Pain Research: A clinical trial report says high-dose CBD outperformed placebo for neuropathic pain, adding to the growing medical interest in CBD-based options. Hemp Business Shock: Virginia’s August deadline could wipe out many hemp products with more than 2mg THC, leaving an 11-month gap before the regulated adult-use market starts. Regulation Watch (Australia): The TGA issued new guidance on advertising restrictions for prescription medicines, including medical cannabis and other high-risk categories. Sleep & Brain Claims: A new omega-3 supplement trial found no boost for memory or cognition, reinforcing the “food first” message over pills. Public Safety: A Supreme Court ruling said marijuana users can’t be barred from owning guns under the Second Amendment, while Canada continues to flag cannabis as a driver impairment risk. Health & Food: Researchers and diet coverage keep circling back to what actually helps—plus more gardening and food-safety reads.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
